0001193125-26-097467
SEC filingARS Pharmaceuticals, Inc. announced fourth quarter and full year 2025 financial results, reporting $28.1 million total revenue including $20.3 million U.S. neffy net product revenue and $72.2 million full year U.S. neffy net product revenue, with $245.0 million in cash supporting operations through cash-flow break-even. The company updated its corporate presentation and provided neffy commercialization and regulatory updates.